UK Advanced Therapy Trials Rise By 7% In 2024, With A 70% increase

In 2024, the advanced therapy clinical trials within the UK have extended to 187, which is a slight 7% increase compared to the previous year. This has seen an estimated rise from 24 to 41 of the phase one trials, a 70% approximate rise. These data are based on the Cell and Gene Therapy Catapult’s (CGT Catapult) UK 2024 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database. The largest portion of ATMP clinical trials in 2024 was in gene therapies, similar to 2023.

Matthew Durdy, Chief Executive of the CGT Catapult, commented, “Advanced therapy clinical trials are important in two regards. They provide a clear indication of the attractiveness of the UK for advanced therapy product development, and they create the skills, capabilities, and environment that mean that patients can access these life-changing drugs more quickly and easily. This data shows the UK’s continued strength on both counts.”

However, as the market becomes more competitive all over the world, the UK will still have its presence in only 9.5% of total clinical trials conducted worldwide and 50% of the clinical trials conducted in Europe in 2024. The new or initiated trial data by CGT Catapult also reveals that the number of new trials in 2024 is 27, while the number of trials in 2023 is 13, indicating the growth in the pipeline of products.